Pfizer-BioNTech says its COVID vaccine 100% effective in teens

Pfizer-BioNTech said their vaccine showed 100 percent efficacy against the coronavirus in children between 12-15 years.

Pfizer-BioNTech said on Wednesday their vaccine showed 100 percent efficacy against the coronavirus in 12 to 15-year-olds, as they eye approval for adolescents to get the jabs before the next school year. Phase-three trials carried out on 2,260 adolescents in the United States “demonstrated 100 percent efficacy and robust antibody responses”, the companies said in a statement. “We plan to submit these data to (US regulator) FDA as a proposed amendment to our Emergency Use Authorisation in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year,” said Pfizer chief executive Albert Bourla.